444 related articles for article (PubMed ID: 26197027)
1. Chemotherapy-induced peripheral neurotoxicity.
Cavaletti G; Marmiroli P
Curr Opin Neurol; 2015 Oct; 28(5):500-7. PubMed ID: 26197027
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
Cavaletti G; Frigeni B; Lanzani F; Mattavelli L; Susani E; Alberti P; Cortinovis D; Bidoli P
Eur J Cancer; 2010 Feb; 46(3):479-94. PubMed ID: 20045310
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced peripheral neuropathy: A current review.
Staff NP; Grisold A; Grisold W; Windebank AJ
Ann Neurol; 2017 Jun; 81(6):772-781. PubMed ID: 28486769
[TBL] [Abstract][Full Text] [Related]
4. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
Knoerl R; Weller E; Halpenny B; Berry D
BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
Argyriou AA; Bruna J; Marmiroli P; Cavaletti G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):51-77. PubMed ID: 21908200
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue.
Cavaletti G; Alberti P; Argyriou AA; Lustberg M; Staff NP; Tamburin S;
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S6-S12. PubMed ID: 31647155
[TBL] [Abstract][Full Text] [Related]
7. Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH.
Streckmann F; Hess V; Bloch W; Décard BF; Ritzmann R; Lehmann HC; Balke M; Koliamitra C; Oschwald V; Elter T; Zahner L; Donath L; Roth R; Faude O
BMJ Open; 2019 Apr; 9(4):e024467. PubMed ID: 31023750
[TBL] [Abstract][Full Text] [Related]
8. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy-induced peripheral neuropathy: an unresolved issue].
Velasco R; Bruna J
Neurologia; 2010 Mar; 25(2):116-31. PubMed ID: 20487712
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.
Cavaletti G
J Peripher Nerv Syst; 2014 Jun; 19(2):66-76. PubMed ID: 24976572
[TBL] [Abstract][Full Text] [Related]
11. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
12. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN).
Stoller S; Capozza S; Alberti P; Lustberg M; Kleckner IR
Support Care Cancer; 2023 Apr; 31(5):293. PubMed ID: 37086308
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.
Argyriou AA; Bruna J; Genazzani AA; Cavaletti G
Nat Rev Neurol; 2017 Aug; 13(8):492-504. PubMed ID: 28664909
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Related Neurotoxicity.
Taillibert S; Le Rhun E; Chamberlain MC
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):81. PubMed ID: 27443648
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neurotoxicity.
Cavaletti G; Marmiroli P
Nat Rev Neurol; 2010 Dec; 6(12):657-66. PubMed ID: 21060341
[TBL] [Abstract][Full Text] [Related]
17. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
[TBL] [Abstract][Full Text] [Related]
19. Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity.
Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB
J Neurol Sci; 2024 Feb; 457():122862. PubMed ID: 38185015
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced neuropathy: A comprehensive survey.
Miltenburg NC; Boogerd W
Cancer Treat Rev; 2014 Aug; 40(7):872-82. PubMed ID: 24830939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]